Drug Target Review

JUNE 15, 2023

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing.

RNA 96

RNA Small Molecule Disease Assay Development 96

Broad Institute

JUNE 30, 2023

Common genetic variants associated with cardiometabolic disease can produce phenotype changes of such small effect that they can be difficult to characterize. Fat cells stained yellow to show the actin cytoskeleton, plasma membrane, and Golgi apparatus. Credit: Phil Kubitz, Claussnitzer lab Fat cells stained blue to show nuclei.

Small Molecule 105

Small Molecule Cell Based Assays Disease Assay Development 105

Elrig

APRIL 29, 2024

My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. There, I supported AI-enabled DD efforts in their small molecule portfolio.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Sygnature Discovery

SEPTEMBER 14, 2023

The biotech will continue partnering with Sygnature to drive its novel, genetically validated cardiovascular disease project pipeline. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases and more.

Small Molecule 52

Small Molecule Assay Development Disease Drug Research 52